Clifford DiLea

586 total citations
24 papers, 438 citations indexed

About

Clifford DiLea is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Hematology. According to data from OpenAlex, Clifford DiLea has authored 24 papers receiving a total of 438 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 8 papers in Radiology, Nuclear Medicine and Imaging and 5 papers in Hematology. Recurrent topics in Clifford DiLea's work include Monoclonal and Polyclonal Antibodies Research (8 papers), HER2/EGFR in Cancer Research (7 papers) and CAR-T cell therapy research (3 papers). Clifford DiLea is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (8 papers), HER2/EGFR in Cancer Research (7 papers) and CAR-T cell therapy research (3 papers). Clifford DiLea collaborates with scholars based in United States, Spain and Switzerland. Clifford DiLea's co-authors include Harold Boxenbaum, Margaret Dugan, Soong T. Chiang, Paul T. Martin, Steven Troy, Richard J. Fruncillo, Peter H. Hinderling, Robert A. Blouin, Pamela S. Becker and Januario E. Castro and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Clifford DiLea

24 papers receiving 407 citations

Peers

Countries citing papers authored by Clifford DiLea

Since Specialization

Citations

This map shows the geographic impact of Clifford DiLea's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Clifford DiLea with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Clifford DiLea more than expected).

Fields of papers citing papers by Clifford DiLea

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Clifford DiLea. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Clifford DiLea. The network helps show where Clifford DiLea may publish in the future.

Co-authorship network of co-authors of Clifford DiLea

This figure shows the co-authorship network connecting the top 25 collaborators of Clifford DiLea. A scholar is included among the top collaborators of Clifford DiLea based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Clifford DiLea. Clifford DiLea is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Recommended phase 2 dose (RP2D) of nemvaleukin alfa in patients (pts) with advanced solid tumors treated with less frequent intravenous (IV) dosing (ARTISTRY-3). 2024 ·Journal of Clinical Oncology ·Sarina A. Piha‐Paul, Justin Call, Alexander I. Spira, (unknown), Maria J. de Miguel, Yangchun Du, Clifford DiLea, (unknown), Nehal J. Lakhani	1
2	744 Assessment of safety and immunologic activity of nemvaleukin alfa in patients with advanced solid tumors treated with less frequent intravenous dosing (ARTISTRY-3) 2023 ·SHILAP Revista de lepidopterología ·Sarina A. Piha‐Paul, Justin Call, Alexander I. Spira, Aránzazu Manzano, Emiliano Calvo, Maria J. de Miguel, (unknown), Yangchun Du, Clifford DiLea, Bhaskar Rege, Rita P. Dalal, (unknown), Nehal J. Lakhani	1
3	Abstract CT125: STRO-002-GM1, a first in human, phase 1 study of STRO-002, an anti-folate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced platinum-resistant/refractory epithelial ovarian cancer (OC), including fallopian tube or primary peritoneal cancers 2020 ·Cancer Research ·R. Wendel Naumann, Denise Uyar, John W. Moroney, Fadi S. Braiteh, Russell J. Schilder, John P. Diaz, Erika Hamilton, Sami Diab, Lainie P. Martin, David M. O’Malley, Richard T. Penson, Clifford DiLea, (unknown), Venita DeAlmeida, Shannon Matheny, Arturo Molina	2
4	138 Phase 1 dose-escalation study of STRO-002, an anti-folate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced platinum-resistant/refractory epithelial ovarian cancer (OC) 2020 ·R. Wendel Naumann, Fadi Braiteh, John P. Diaz, Erika Hamilton, Sami Diab, Russell J. Schilder, John W. Moroney, Lainie P. Martin, Denise Uyar, David M. O’Malley, Richard T. Penson, Clifford DiLea, (unknown), Venita DeAlmeida, (unknown), Shannon Matheny, A. Molina	2
5	Preliminary Results of an Ongoing Phase 1 Dose Escalation Study of the Novel Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with B-Cell Non-Hodgkin Lymphoma 2020 ·Blood ·Nirav N. Shah, (unknown), Leslie Popplewell, Charalambos Andreadis, Jason M. Melear, Alexander I. Spira, (unknown), Sudhir Manda, John M. Burke, Saurabh Chhabra, Jeff P. Sharman, Amrita Krishnan, Nina Shah, Clifford DiLea, (unknown), (unknown), Shannon Matheny, John P. Leonard, Arturo Molina	8
6	Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies 2019 ·Blood ·Nirav N. Shah, Amrita Krishnan, Nina Shah, John M. Burke, Jason M. Melear, Alexander I. Spira, Leslie Popplewell, Charalambos Andreadis, Saurabh Chhabra, Jeff P. Sharman, Jonathan L. Kaufman, Jonathon B. Cohen, Rubén Niesvizky, Thomas G. Martin, Clifford DiLea, (unknown), Shannon Matheny, John P. Leonard, Arturo Molina	16
7	Phase Ib Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma 2014 ·Blood ·Irene M. Ghobrial, Raymond P. Perez, Rachid Baz, Paul G. Richardson, Kenneth C. Anderson, Peter Sabbatini, Clifford DiLea, Pina M. Cardarelli, Mark Wade, Guan Xing, Andres Gutierrez, Lewis Cohen, Pamela S. Becker	10
8	Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788 2012 ·Clinical Cancer Research ·José Baselga, Alain C. Mita, Patrick Schöffski, Herlinde Dumez, Federico Rojo, Josep Tabernero, Clifford DiLea, William Mietlowski, (unknown), (unknown), Margaret Dugan, Kathryn Parker, Eric Walk, A. van Oosterom, Erika Martinelli, Chris H. Takimoto	14
9	Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients 2012 ·Cancer Chemotherapy and Pharmacology ·David A. Reardon, Charles A. Conrad, Timothy F. Cloughesy, Michael D. Prados, Henry S. Friedman, Kenneth Aldape, Paul S. Mischel, (unknown), Clifford DiLea, (unknown), William Mietlowski, Margaret Dugan, Wei Chen, W.K. Alfred Yung	50
10	Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma 2011 ·Cancer Chemotherapy and Pharmacology ·David A. Reardon, Timothy F. Cloughesy, Jeremy N. Rich, W.K. Alfred Yung, Lotus Yung, Clifford DiLea, (unknown), Margaret Dugan, William Mietlowski, Andrea Maes, Charles A. Conrad	11
11	Comparative in Vitro Cellular Data Alone Is Insufficient to Predict Clinical Responses and Guide Choice of BCR-ABL Inhibitor to Treat Imatinib-Resistant Chronic Myeloid Leukemia. 2009 ·Blood ·Pierre Laneuville, Clifford DiLea, Jürgen Mestan, Ophelia Yin, Richard C. Woodman, Paul W. Manley	4
12	Phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: A pharmacokinetic (PK)-pharmacodynamic (PD) study to identify the optimal therapeutic dose regimen 2005 ·Journal of Clinical Oncology ·José Baselga, Federico Rojo, Herlinde Dumez, (unknown), Chris H. Takimoto, Josep Tabernero, Clifford DiLea, Kathryn Parker, Margaret Dugan, A.T. van Oosterom	24
13	A PK-PD dose optimization strategy for the microtubule stabilizing agent ABJ879 2004 ·Cancer Research ·Clifford DiLea, Markus Wartmann, Sauveur-Michel Maira, Josef Brueggen, Chiaki Tanaka, Kurt C. Sizer, Margaret Dugan	1
14	Pharmacokinetics of E5564, a Lipopolysaccharide Antagonist, in Patients with Impaired Hepatic Function 2003 ·The Journal of Clinical Pharmacology ·Earvin Liang, Y. Nancy Wong, (unknown), Richard Kao, Mark T. Marino, Clifford DiLea	6
15	SAFETY AND PHARMACOKINETIC PROFILE OF ASCENDING SINGLE DOSES OF ORAL LIQUID SIROLIMUS (Rapamycin) IN PEDIATRIC PATIENTS WITH STABLE CHRONIC RENAL FAILURE. 1999 ·Transplantation ·Amir Tejani, Steven R. Alexander, E. Kohaut, David M. Briscoe, Gary Lerner, Robert S. Ettinger, Clifford DiLea, Johann Zimmermann	3
16	Pharmacokinetics of once-daily venlafaxine extended release in healthy volunteers 1997 ·Current Therapeutic Research ·Steven Troy, Clifford DiLea, Paul T. Martin, Cathie Leister, Richard J. Fruncillo, Soong T. Chiang	17
17	Bioavailability of once-daily venlafaxine extended release compared with the immediate-release formulation in healthy adult volunteers 1997 ·Current Therapeutic Research ·Steven Troy, Clifford DiLea, Paul T. Martin, A. Rosen, Richard J. Fruncillo, Soong T. Chiang	18
18	First‐Time‐in‐Human Dose Selection: Allometric Thoughts and Perspectives 1995 ·The Journal of Clinical Pharmacology ·Harold Boxenbaum, Clifford DiLea	123
19	Comparative kinetics of sematilide in four species. 1993 ·Drug Metabolism and Disposition ·Peter H. Hinderling, Clifford DiLea, (unknown), (unknown)	22
20	The Pharmacokinetics of Oral Isradipine in Normal Volunteers 1988 ·The Journal of Clinical Pharmacology ·G. Dennis Clifton, Robert A. Blouin, Clifford DiLea, Horst Schran, Alan E. Hassell, Leonard Gonasun, Thomas S. Foster	36

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact